Skip to content
10-K

Annual Report

Allogene Therapeutics, Inc. ALLO

0001737287-25-000036

← back to feed
Filed
Mar 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 7, 2025 217.26M sh
Shares Diluted FY 2024 · Dec 31, 2023 156.93M sh
Capex FY 2024 · Dec 31, 2023 $1.52M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$237.73M
Cash And Equivalents FY 2024 · Dec 31, 2023 $83.16M
Current Liabilities FY 2024 · Dec 31, 2023 $37.08M
Total Liabilities FY 2024 · Dec 31, 2023 $130.6M
Current Assets FY 2024 · Dec 31, 2023 $459.12M
Total Assets FY 2024 · Dec 31, 2023 $642.84M
Eps Diluted FY 2024 · Dec 31, 2023 −$2.09
Eps Basic FY 2024 · Dec 31, 2023 −$2.09
Sga Expense FY 2024 · Dec 31, 2023 $71.67M
Rd Expense FY 2024 · Dec 31, 2023 $242.91M
Net Income FY 2024 · Dec 31, 2023 −$327.27M
Operating Income FY 2024 · Dec 31, 2023 −$327.74M
Revenue FY 2024 · Dec 31, 2023 $95K